A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 56, Issue 10, 2015, Pages 2863-2869

  Wagner Johnston, Nina D ^a   Goy, Andrè ^b   Rodriguez, Maria A ^c   Ehmann, W Christopher ^d   Hamlin, Paul A ^e   Radford, John ^f   Thieblemont, Catherine ^g   Suh, Cheolwon ^h   Sweetenham, John ⁱ   Huang, Yifan ^j   Sullivan, Sharon T ^j   Vandendries, Erik R ^j   Gisselbrecht, Christian ^g  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d PENN STATE CANCER INSTITUTE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g SAINT LOUIS HOSPITAL   (France)

^h University of Ulsan College of Medicine   (South Korea)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j PFIZER INC   (United States)

more..

Author keywords

autologous; DLBCL; immunotherapy; Inotuzumab ozogamicin; rituximab; transplant

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INOTUZUMAB OZOGAMICIN; PLERIXAFOR; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATRIAL FIBRILLATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; CYTOMEGALOVIRUS INFECTION; DECREASED APPETITE; DELIRIUM; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROBACTERIACEAE INFECTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRAFT FAILURE; HEADACHE; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION; INFESTATION; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY FAILURE; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VEIN OCCLUSION; VOMITING; ADVERSE EFFECTS; AUTOTRANSPLANTATION; CANCER STAGING; CLINICAL TRIAL; DRUG RESISTANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; ODDS RATIO; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROCEDURES; PROGNOSIS; RECURRENT DISEASE; REMISSION; RETREATMENT; STEM CELL MOBILIZATION; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETREATMENT; RITUXIMAB; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938897233     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1017821     Document Type: Article

References (22)

1. Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 2013;31:573-583.
2. Hinman LM, Hamann PR, Wallace R, et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res 1993;53:3336-3342.
3. Lee M, Dunne T, Chang C, et al. Calicheamicins, a novel family of antitumor antibiotics. 4. Structural elucidations of calicheamicins. J Am Chem Soc 1992;114:985-997.
4. Thorson J, Sievers E, Ahlert J, et al. Understanding and exploiting nature's chemical arsenal: The past, present and future of calicheamicin research. Curr Pharm Des 2000;6:1841-1879.
5. Zein N, Sinha A, McGahren W, et al. Calicheamicin ?1: an antitumor antibiotic that cleaves double-stranded DBA site specifically. Science 1988;240:1198-1201.
6. Cesano A, Gayko U, Brannan C. Differential expression of CD22 in indolent and aggressive non-Hodgkin's lymphoma (NHL): implications for targeted immunotherapy. Blood 2002;100(Suppl. 1): Abstract 1358.
7. DiJoseph JF, Goad ME, Dougher MM, et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2004;10:8620-8629.
8. Vaickus L, Ball ED, Foon KA. Immune markers in hematologic malignancies. Crit Rev Oncol Hematol 1991;11:267-297.
9. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989-1996.
10. Cheson D, Pfistner B, Juweid M, et al. Revised response criteria for malignant lymphomas. J Clin Oncol 2007;25:579-586.
11. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
12. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184-4190.
13. Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008;93:1829-1836.
14. El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007;18:1363-1368.
15. Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and followup. Ann Oncol 2010;21:v172-v174.
16. Lopez A, Gutierrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 2008;80:127-132.
17. Advani A, Coiffier B, Czuczman M, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010;12:2085-2093.
18. Willner I. Veno-occlusive disease. Curr Treat Options Gastroenterol 2002;5:465-469.
19. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for blood and marrow transplantation. Blood 1998;92:3599-3604.
20. Puig N, DeLa Rubia J, Remigia J, et al. Morbidity and transplantrelated mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 2006;47:1488-1494.
21. Gomez Almaguer D, Aung S, Kotb R. Inotuzumab ozogamicin plus rituximab versus definted investigator's choice in CD20?/CD22 ? follicular non-Hodgkin lymphoma. Haematologica 2012; 97(Suppl. 1): Abstract 0799.
22. DeAngelo DJ, Stock W, Shustov AR. Weekly inotozumab ozogamicin (InO) in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL). Blood 2013; 122(Suppl. 1): Abstract 3906.